Comparative Pharmacology
Head-to-head clinical analysis: ACLOVATE versus ARAZLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACLOVATE versus ARAZLO.
ACLOVATE vs ARAZLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
Topical: Apply 0.045% gel once daily to affected areas of the face.
None Documented
None Documented
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid